← Back to Screener
Rezolute, Inc. Common Stock (NV) (RZLT)
Price$3.61
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-81.73%
Price vs S&P 500 (4W)-4.97%
VGM Score39.97
Market Capitalization$317.76M
All Metrics
Book Value / Share (Quarterly)$1.21
P/TBV (Annual)3.69x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.76
Price vs S&P 500 (YTD)28.90%
EPS (TTM)$-0.81
10-Day Avg Trading Volume1.13M
EPS Excl Extra (TTM)$-0.81
EPS (Annual)$-0.98
ROI (Annual)-45.90%
Cash / Share (Quarterly)$1.25
ROA (Last FY)-42.40%
EBITD / Share (TTM)$-0.86
ROE (5Y Avg)-50.92%
Cash Flow / Share (Annual)$-0.79
P/B Ratio2.72x
P/B Ratio (Quarterly)2.50x
Net Income / Employee (Annual)$-1,048,100
Net Interest Coverage (TTM)-5.32x
ROA (TTM)-54.48%
EPS Incl Extra (Annual)$-0.98
Current Ratio (Annual)14.37x
Quick Ratio (Quarterly)15.61x
3-Month Avg Trading Volume2.24M
52-Week Price Return-20.58%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.25
52-Week High$11.46
EPS Excl Extra (Annual)$-0.98
Tangible BV CAGR (5Y)2.95%
26-Week Price Return-65.80%
Quick Ratio (Annual)14.09x
13-Week Price Return0.30%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)15.84x
Enterprise Value$306.53M
Book Value / Share Growth (5Y)8.24%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.93
3-Month Return Std Dev77.18%
Net Income / Employee (TTM)$-1,147,700
ROE (Last FY)-45.90%
Net Interest Coverage (Annual)-19.31x
EPS Basic Excl Extra (Annual)$-0.98
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.81
ROI (TTM)-58.82%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.25
Price vs S&P 500 (52W)-48.78%
Year-to-Date Return39.83%
5-Day Price Return1.54%
EPS Normalized (Annual)$-0.98
ROA (5Y Avg)-42.37%
Month-to-Date Return3.13%
Cash Flow / Share (TTM)$-1.10
EBITD / Share (Annual)$-1.05
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-45.33%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.81
P/TBV (Quarterly)3.69x
P/B Ratio (Annual)2.39x
Book Value / Share (Annual)$1.86
Price vs S&P 500 (13W)-9.44%
Beta0.62x
Revenue / Share (TTM)$0.00
ROE (TTM)-58.82%
52-Week Low$1.07
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q3 26-0.16est. -0.18
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.00
4.00
4.00
4.13
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
RZLTRezolute, Inc. Common Stock (NV) | — | — | D | $3.61 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Rezolute is a clinical-stage biopharmaceutical company developing therapies for rare metabolic diseases, including congenital hyperinsulinism, a rare endocrine disorder characterized by excessive insulin production and hypoglycemia. Its pipeline candidates aim to improve patient outcomes with reduced treatment burdens. Value creation depends on successful clinical development and regulatory approval.